Chemotherapy + IMPT for Endometrial Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
A phase 2 study with the primary objective of testing treatment compliance of Upfront Intensity Modulated Proton Beam Therapy (IMPT) and Concurrent Chemotherapy (UPPROACH) for Post-operative Treatment in Loco-regionally Advanced Endometrial Cancer is non-inferior to the historic compliance rate of the chemoradiation arm of GOG 258 study
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the combination of chemotherapy drugs Carboplatin and Paclitaxel, along with Intensity Modulated Proton Therapy, generally safe for humans?
The combination of Carboplatin and Paclitaxel has been studied for endometrial cancer and is generally considered to have acceptable levels of toxicity, though some patients experienced significant side effects like hematologic toxicity (blood-related side effects) and neuropathy (nerve damage). Intensity Modulated Proton Therapy has been evaluated in combination with these drugs for cervical cancer, focusing on determining safe dosage levels.12345
How does the treatment of Chemotherapy + IMPT for Endometrial Cancer differ from other treatments?
This treatment is unique because it combines chemotherapy drugs, carboplatin and paclitaxel, with Intensity Modulated Proton Therapy (IMPT), a type of radiation therapy that uses protons to precisely target tumors, potentially reducing damage to surrounding healthy tissues compared to traditional radiation.14678
What data supports the effectiveness of the treatment for endometrial cancer?
Research shows that the combination of carboplatin and paclitaxel is effective in reducing tumor size in patients with advanced or recurrent endometrial cancer, with a significant number of patients experiencing partial responses. This combination is considered a standard initial therapy for advanced endometrial cancer, demonstrating activity against tumors with acceptable levels of side effects.13459
Who Is on the Research Team?
Pranshu Mohindra, MD
Principal Investigator
University of Maryland/Maryland Proton Treatment Center
Are You a Good Fit for This Trial?
This trial is for adults with advanced endometrial cancer who've had a hysterectomy and possibly other related surgeries. It's open to those with certain stages of cancer, including stage IVA or IA-III if it's clear cell, serous papillary carcinoma, or carcinosarcoma. Participants need normal organ function and no history of heart issues in the past 3 months. They can't have had prior chemotherapy for any cancer.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Concurrent Chemoradiation
Participants receive concurrent carboplatin and paclitaxel chemotherapy with Intensity Modulated Proton Therapy (IMPT)
Chemotherapy
Participants complete full 6 cycles of chemotherapy with carboplatin and paclitaxel
Follow-up
Participants are monitored for late GI and urinary toxicity
What Are the Treatments Tested in This Trial?
Interventions
- Carboplatin and Paclitaxel
- Pelvic IMPT (Intensity Modulated Proton Therapy)
Carboplatin and Paclitaxel is already approved in European Union, United States, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Maryland, Baltimore
Lead Sponsor